ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Price, Forecast & Analysis
NYSEARCA:ATNM • US00507W2061
ATNM Key Statistics, Chart & Performance
The current stock price of ATNM is 1.13 USD. In the past month the price decreased by -16.54%. In the past year, price decreased by -3.48%.
ATNM Technical Analysis
ATNM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNM. The financial health of ATNM is average, but there are quite some concerns on its profitability.
ATNM Financial Highlights
Over the last trailing twelve months ATNM reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 21.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.12% | ||
| ROE | -215.83% | ||
| Debt/Equity | 0 |
ATNM Forecast & Estimates
11 analysts have analysed ATNM and the average price target is 5.1 USD. This implies a price increase of 351.33% is expected in the next year compared to the current price of 1.13.
For the next year, analysts expect an EPS growth of 13.26% and a revenue growth -76.23% for ATNM
ATNM Ownership
ATNM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.14 | 402.079B | ||
| AMGN | AMGEN INC | 16.33 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.4 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.2 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.26 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.66 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.99 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATNM
Company Profile
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Company Info
ACTINIUM PHARMACEUTICALS INC
100 Park Ave., 23Rd Floor
New York City NEW YORK 10016 US
CEO: Sandesh Seth
Employees: 37
Phone: 16466773870
ACTINIUM PHARMACEUTICALS INC / ATNM FAQ
What does ATNM do?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Can you provide the latest stock price for ACTINIUM PHARMACEUTICALS INC?
The current stock price of ATNM is 1.13 USD. The price increased by 1.8% in the last trading session.
What is the dividend status of ACTINIUM PHARMACEUTICALS INC?
ATNM does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATNM stock?
ATNM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for ACTINIUM PHARMACEUTICALS INC?
ACTINIUM PHARMACEUTICALS INC (ATNM) currently has 37 employees.
What is the market capitalization of ATNM stock?
ACTINIUM PHARMACEUTICALS INC (ATNM) has a market capitalization of 35.26M USD. This makes ATNM a Nano Cap stock.